Skip to contentpdufa.bio

TNG456 (brain-penetrant PRMT5 inhibitor)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

TNG456 (brain-penetrant PRMT5 inhibitor) is a Tango Therapeutics, Inc. program in lung cancer, glioblastoma and other cancers. Its next catalyst is a Readout in Jan 2027.

TNGX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: lung cancer, glioblastoma and other cancers. Sponsor: Tango Therapeutics, Inc. (TNGX). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Jan 2027TNGX

Specialist biotech funds holding TNGX, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
RTW Investments14,048,477$350.5 millionfiled November 16, 2026
OrbiMed Advisors2,777,621$69.3 millionfiled November 16, 2026
Perceptive Advisors2,693,000$67.2 millionfiled November 16, 2026
Cormorant Asset Management700,000$17.5 millionfiled November 16, 2026
Baker Bros. Advisors333,333$8.3 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is TNG456 (brain-penetrant PRMT5 inhibitor)'s next FDA decision or readout?

The next tracked catalyst for TNG456 (brain-penetrant PRMT5 inhibitor) is a Readout in Jan 2027.

What happened at TNG456 (brain-penetrant PRMT5 inhibitor)'s most recent FDA decision?

No FDA decision for TNG456 (brain-penetrant PRMT5 inhibitor) is in our archive yet.

What is TNG456 (brain-penetrant PRMT5 inhibitor) used for?

In our records TNG456 (brain-penetrant PRMT5 inhibitor) is under review or in development for lung cancer, glioblastoma and other cancers.

Who makes TNG456 (brain-penetrant PRMT5 inhibitor)?

Tango Therapeutics, Inc. (TNGX).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.